Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Maravai LifeSciences Holdings Inc MRVI

Technology Scientific & Technical Instruments
Maravai LifeSciences Holdings, Inc. is a life sciences company. The Company provides products that enable the development of drug therapies, diagnostics and vaccines and to support research on human diseases. Its companies provide products and services in the fields of nucleic acid synthesis and biologics safety testing to various biopharmaceutical, vaccine, diagnostics, and cell and gene... see more

Recent & Breaking News (NDAQ:MRVI)

Maravai LifeSciences Announces March 2023 Investor Conference Schedule

GlobeNewswire March 8, 2023

Maravai LifeSciences Reports Fourth Quarter and Full Year 2022 Financial Results

GlobeNewswire February 22, 2023

Maravai LifeSciences to Host Earnings Conference Call on Wednesday, February 22, 2023

GlobeNewswire February 1, 2023

Maravai LifeSciences Announces Updated CEO Leadership Transition Plans

GlobeNewswire December 1, 2022

Maravai LifeSciences Named to the 2022 Deloitte Technology Fast 500(TM) List of Fastest-Growing Companies in North America

GlobeNewswire November 16, 2022

New Kit Predicts Retroviral Particle Clearance in Biopharmaceutical Manufacturing

GlobeNewswire November 7, 2022

Maravai LifeSciences Announces November and December 2022 Investor Conference Schedule

GlobeNewswire November 3, 2022

Maravai LifeSciences Reports Third Quarter 2022 Financial Results

GlobeNewswire November 2, 2022

Maravai LifeSciences Temporarily Reinstates Carl Hull as CEO Amidst Pending Noncompetition Litigation

GlobeNewswire October 19, 2022

Maravai LifeSciences To Host Earnings Conference Call on Wednesday, November 2, 2022

GlobeNewswire October 18, 2022

Maravai LifeSciences Announces CEO Leadership Transition

GlobeNewswire October 3, 2022

TriLink BioTechnologies, Part of Maravai LifeSciences, Expands its mRNA Raw Material Offering with the First GMP-grade Modified Nucleoside-Triphosphate Product

GlobeNewswire September 13, 2022

Maravai LifeSciences Announces September 2022 Investor Conference Schedule

GlobeNewswire August 15, 2022

CORRECTION: Maravai Lifesciences Reports Second Quarter 2022 Financial Results

GlobeNewswire August 4, 2022

Maravai Lifesciences Reports Second Quarter 2022 Financial Results

GlobeNewswire August 4, 2022

Maravai LifeSciences To Host Earnings Conference Call on Thursday, August 4, 2022

GlobeNewswire July 19, 2022

TriLink BioTechnologies, part of Maravai LifeSciences, Expands R&D Leadership Team

GlobeNewswire July 6, 2022

Maravai LifeSciences Strengthens Executive Leadership Team to Support Long-Term Growth

GlobeNewswire June 27, 2022

TriLink BioTechnologies, Part of Maravai LifeSciences, Announces Cooperative Agreement With Department of Defense

GlobeNewswire May 24, 2022

Maravai LifeSciences Announces May and June 2022 Investor Conference Schedule

GlobeNewswire May 11, 2022